Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

BUY
$15.14 - $19.14 $0 - $0
0 New
0 $0
Q2 2024

Jul 23, 2024

BUY
$14.62 - $18.42 $0 - $0
0 New
0 $0
Q1 2024

Apr 30, 2024

BUY
$17.79 - $30.86 $0 - $0
0 New
0 $0
Q4 2023

Feb 07, 2024

BUY
$20.78 - $31.77 $0 - $0
0 New
0 $0
Q3 2023

Oct 30, 2023

BUY
$20.84 - $33.47 $0 - $0
0 New
0 $0
Q3 2023

Oct 25, 2023

SELL
$20.84 - $33.47 $2,084 - $3,347
-100 Closed
0 $0
Q4 2022

Jan 30, 2023

BUY
$14.2 - $18.63 $1,420 - $1,863
100 New
100 $0
Q3 2022

Nov 15, 2022

SELL
$14.11 - $18.27 $1,411 - $1,827
-100 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$19.4 - $27.42 $1,939 - $2,742
-100 Reduced 50.0%
100 $0
Q1 2021

May 13, 2021

SELL
$25.02 - $54.99 $2,502 - $5,499
-100 Reduced 33.33%
200 $5,000
Q4 2020

Feb 02, 2021

BUY
$41.04 - $56.79 $12,312 - $17,037
300 New
300 $16,000
Q3 2020

Nov 13, 2020

SELL
$36.42 - $57.0 $18,027 - $28,215
-495 Closed
0 $0
Q2 2020

Aug 13, 2020

SELL
$39.26 - $52.73 $8,637 - $11,600
-220 Reduced 30.77%
495 $24,000
Q1 2020

May 13, 2020

BUY
$31.65 - $46.87 $22,629 - $33,512
715 New
715 $30,000
Q4 2019

Feb 14, 2020

BUY
$36.21 - $51.4 $0 - $0
0 New
0 $0
Q3 2019

Nov 13, 2019

BUY
$22.22 - $44.01 $0 - $0
0 New
0 $0
Q2 2019

Aug 13, 2019

BUY
$23.32 - $28.12 $0 - $0
0 New
0 $0
Q1 2019

May 15, 2019

SELL
$16.17 - $27.38 $2,069 - $3,504
-128 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$14.32 - $22.92 $157 - $252
11 Added 9.4%
128 $2,000
Q3 2018

Nov 13, 2018

BUY
$13.03 - $21.81 $1,524 - $2,551
117 New
117 $2,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.39B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.